OTCMKTS:CDXI

Cardax Competitors

$2.00

-0.10 (-4.76 %)

(As of 04/14/2021 01:30 PM ET)

Add

Compare

Today's Range

$2.00

Now: $2.00▼

$2.00

50-Day Range

$1.78

MA: $2.15▼

$3.00

52-Week Range

$1.15

Now: $2.00▼

$15.00

Volume166 shs

Average Volume476 shs

Market Capitalization$1.59 million

P/E RatioN/A

Dividend YieldN/A

Beta1.35

Cardax (OTCMKTS:CDXI) Vs. WCUI, KAYS, ISCO, IPCIF, BCTXF, and FWDG

Should you be buying CDXI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Cardax, including Wellness Center USA (WCUI), Kaya (KAYS), International Stem Cell (ISCO), Intellipharmaceutics International (IPCIF), BriaCell Therapeutics (BCTXF), and FutureWorld (FWDG).

Cardax vs. Wellness Center USA Stock

Cardax (OTCMKTS:CDXI) and Wellness Center USA (OTCMKTS:WCUI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cardax and Wellness Center USA, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardax	0	0	0	0	N/A
Wellness Center USA	0	0	0	0	N/A

Insider & Institutional Ownership

8.7% of Cardax shares are held by institutional investors. Comparatively, 0.1% of Wellness Center USA shares are held by institutional investors. 14.1% of Wellness Center USA shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Cardax and Wellness Center USA's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardax	$710,000.00	2.24	$-5,090,000.00	N/A	N/A
Wellness Center USA	$30,000.00	228.21	$-2,390,000.00	N/A	N/A

Wellness Center USA has lower revenue, but higher earnings than Cardax.

Risk and Volatility

Cardax has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Wellness Center USA has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Profitability

This table compares Cardax and Wellness Center USA's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardax	-891.77%	N/A	-297.64%
Wellness Center USA	N/A	N/A	-1,809.19%

Cardax vs. Kaya Stock

Cardax (OTCMKTS:CDXI) and Kaya (OTCMKTS:KAYS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cardax and Kaya, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardax	0	0	0	0	N/A
Kaya	0	1	0	0	2.00

Insider & Institutional Ownership

8.7% of Cardax shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Cardax and Kaya's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardax	$710,000.00	2.24	$-5,090,000.00	N/A	N/A
Kaya	$1.01 million	6.71	$7.80 million	N/A	N/A

Kaya has higher revenue and earnings than Cardax.

Risk and Volatility

Cardax has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Kaya has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.

Profitability

This table compares Cardax and Kaya's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardax	-891.77%	N/A	-297.64%
Kaya	-1,558.07%	N/A	-586.93%

Summary

Cardax beats Kaya on 4 of the 7 factors compared between the two stocks.

Cardax vs. International Stem Cell Stock

Cardax (OTCMKTS:CDXI) and International Stem Cell (OTCMKTS:ISCO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cardax and International Stem Cell, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardax	0	0	0	0	N/A
International Stem Cell	0	0	0	0	N/A

Valuation and Earnings

This table compares Cardax and International Stem Cell's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardax	$710,000.00	2.24	$-5,090,000.00	N/A	N/A
International Stem Cell	$9.47 million	0.57	$-4,260,000.00	N/A	N/A

International Stem Cell has higher revenue and earnings than Cardax.

Profitability

This table compares Cardax and International Stem Cell's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardax	-891.77%	N/A	-297.64%
International Stem Cell	-55.56%	N/A	-72.21%

Insider & Institutional Ownership

8.7% of Cardax shares are held by institutional investors. 81.7% of International Stem Cell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Cardax has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, International Stem Cell has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.

Summary

International Stem Cell beats Cardax on 5 of the 8 factors compared between the two stocks.

Cardax vs. Intellipharmaceutics International Stock

Intellipharmaceutics International (OTCMKTS:IPCIF) and Cardax (OTCMKTS:CDXI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Intellipharmaceutics International and Cardax, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellipharmaceutics International	0	0	0	0	N/A
Cardax	0	0	0	0	N/A

Earnings and Valuation

This table compares Intellipharmaceutics International and Cardax's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellipharmaceutics International	$3.48 million	1.57	$-8,090,000.00	N/A	N/A
Cardax	$710,000.00	2.24	$-5,090,000.00	N/A	N/A

Cardax has lower revenue, but higher earnings than Intellipharmaceutics International.

Profitability

This table compares Intellipharmaceutics International and Cardax's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intellipharmaceutics International	-232.11%	N/A	-81.71%
Cardax	-891.77%	N/A	-297.64%

Insider & Institutional Ownership

8.7% of Cardax shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Intellipharmaceutics International has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Cardax has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500.

Summary

Intellipharmaceutics International beats Cardax on 4 of the 7 factors compared between the two stocks.

Cardax vs. BriaCell Therapeutics Stock

BriaCell Therapeutics (OTCMKTS:BCTXF) and Cardax (OTCMKTS:CDXI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Insider & Institutional Ownership

0.1% of BriaCell Therapeutics shares are owned by institutional investors. Comparatively, 8.7% of Cardax shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares BriaCell Therapeutics and Cardax's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BriaCell Therapeutics	N/A	N/A	$-3,680,000.00	N/A	N/A
Cardax	$710,000.00	2.24	$-5,090,000.00	N/A	N/A

BriaCell Therapeutics has higher earnings, but lower revenue than Cardax.

Analyst Recommendations

This is a breakdown of recent ratings for BriaCell Therapeutics and Cardax, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BriaCell Therapeutics	0	0	0	0	N/A
Cardax	0	0	0	0	N/A

Profitability

This table compares BriaCell Therapeutics and Cardax's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BriaCell Therapeutics	N/A	N/A	-786.77%
Cardax	-891.77%	N/A	-297.64%

Volatility & Risk

BriaCell Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Cardax has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500.

Summary

Cardax beats BriaCell Therapeutics on 4 of the 6 factors compared between the two stocks.

Cardax vs. FutureWorld Stock

FutureWorld (OTCMKTS:FWDG) and Cardax (OTCMKTS:CDXI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Insider and Institutional Ownership

8.7% of Cardax shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares FutureWorld and Cardax's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FutureWorld	N/A	N/A	N/A	N/A	N/A
Cardax	$710,000.00	2.24	$-5,090,000.00	N/A	N/A

FutureWorld has higher earnings, but lower revenue than Cardax.

Analyst Ratings

This is a summary of recent recommendations and price targets for FutureWorld and Cardax, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FutureWorld	0	0	0	0	N/A
Cardax	0	0	0	0	N/A

Profitability

This table compares FutureWorld and Cardax's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FutureWorld	N/A	N/A	N/A
Cardax	-891.77%	N/A	-297.64%

Risk and Volatility

FutureWorld has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Cardax has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500.

Summary

Cardax beats FutureWorld on 3 of the 5 factors compared between the two stocks.